EUVIMEDEUVIMED entdecken
Open Access

Independent Validation of the International Grading System for Medullary Thyroid Carcinoma: A Single Institution Experience

Daniel J Lubin, David Blake Behrman, Subir Goyal, Kelly Magliocca, Qiuying Shi, Amy Y Chen, Kartik Viswanathan

Modern Pathology · 2023-09 · 36 (9) · 100235

DOI: 10.1016/j.modpat.2023.100235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2023-09. Verfasst von Daniel J Lubin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Emory University Hospital Midtown, Atlanta, Georgia; Winship Cancer Institute, Emory University Hospital, Atlanta, Georgia. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, Winship Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medullary thyroid carcinoma (MTC), an uncommon C cell thyroid malignancy, accounts for a disproportionate number of thyroid cancer deaths. To predict MTC clinical behavior, the recent international MTC grading system (IMTCGS) was published combining features from the Memorial Sloan Kettering Cancer Center and Royal North Shore Hospital grading systems that incorporates mitotic count, necrosis, and Ki67 proliferative index (Ki67PI). The IMTCGS appears promising, but independent validation data are limited. Here, we applied the IMTCGS to our institutional MTC cohort and assessed its ability to predict clinical outcomes. Our cohort comprised 87 MTCs (30 germline and 57 sporadic). Slides for each case were reviewed by 2 pathologists and histologic features recorded. Ki67 immunostaining was performed on all cases. Each MTC was graded with the IMTCGS based on tumor necrosis, Ki67PI, and mitotic count. Cox regression analysis was performed to assess the impact of various clinical and pathological data on disease outcomes, including overall survival (OS), disease-free survival, disease-specific survival (DSS), and distant metastasis-free survival. In our MTC cohort, 18.4% (n = 16/87) were IMTCGS high grade. IMTCGS grade was strongly prognostic for OS, disease-free survival, DSS, and distant metastasis-free survival on univariate analysis and multivariable analysis in both the entire MTC cohort and in the sporadic subset. Among the individual IMTCGS parameters, while all 3 were associated with poorer survival outcomes on univariate analysis, necrosis had the strongest association with all survival parameters on multivariable analysis, whereas Ki67PI or mitotic count was associated only with OS and DSS. This retrospective study independently demonstrates that the IMTCGS is valid for grading MTCs. Our findings support incorporating IMTCGS into routine pathology practice. IMTCGS grading may help clinicians to better predict the prognosis of MTC. Future studies may shed light on how MTC grading should impact treatment protocols.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsCarcinoma, NeuroendocrineHumansRetrospective StudiesKi-67 AntigenPrognosisNecrosis

Stichwörter der Autor:innen

international grading systemmedullary thyroid carcinomathyroidvalidation

Substanzen

Ki-67 Antigen

Autor:innen und Institutionen

  • Department of Pathology, Emory University Hospital Midtown, Atlanta, Georgia; Winship Cancer Institute, Emory University Hospital, Atlanta, Georgia.
  • Department of Pathology, Emory University Hospital Midtown, Atlanta, Georgia.
  • Winship Cancer Institute, Emory University Hospital, Atlanta, Georgia; Biostatistics Shared Resource, Winship Cancer Institute of Emory University, Decatur, Georgia.
  • Winship Cancer Institute, Emory University Hospital, Atlanta, Georgia; Division of Endocrine Surgery, Department of Otolaryngology, Emory University Hospital Midtown, Atlanta, Georgia.
  • Department of Pathology, Emory University Hospital Midtown, Atlanta, Georgia; Winship Cancer Institute, Emory University Hospital, Atlanta, Georgia. Electronic address: kartik.viswanathan@emory.edu.

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Winship Cancer Institute
  • National Institutes of Health
  • Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine

Zitieren

APA

Lubin, D. J., Behrman, D. B., Goyal, S., Magliocca, K., Shi, Q., Chen, A. Y., & Viswanathan, K. (2023). Independent Validation of the International Grading System for Medullary Thyroid Carcinoma: A Single Institution Experience. Modern Pathology, 36(9), 100235. https://doi.org/10.1016/j.modpat.2023.100235

Vancouver

Lubin DJ, Behrman DB, Goyal S, Magliocca K, Shi Q, Chen AY, et al. Independent Validation of the International Grading System for Medullary Thyroid Carcinoma: A Single Institution Experience. Modern Pathology. 2023;36(9):100235. doi:10.1016/j.modpat.2023.100235

BibTeX
@article{Lubin2023,
  author = {Lubin, Daniel J and Behrman, David Blake and Goyal, Subir and Magliocca, Kelly and Shi, Qiuying and Chen, Amy Y and Viswanathan, Kartik},
  title = {Independent Validation of the International Grading System for Medullary Thyroid Carcinoma: A Single Institution Experience},
  journal = {Modern Pathology},
  year = {2023},
  volume = {36},
  number = {9},
  pages = {100235},
  doi = {10.1016/j.modpat.2023.100235}
}
Kostenlos starten →